Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback